Literature DB >> 32396855

Expanding the Role for Immunotherapy in Triple-Negative Breast Cancer.

Peter Savas1, Sherene Loi2.   

Abstract

PD-1 axis blockade, in combination with chemotherapy, improves outcomes in advanced triple-negative breast cancer that is PD-L1 positive. The phase 3 KEYNOTE-522 trial now shows that the addition of pembrolizumab to chemotherapy improves pathological complete response rates regardless of PD-L1 status and appears to improve survival.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Year:  2020        PMID： 32396855     DOI： 10.1016/j.ccell.2020.04.007

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  9 in total

1.  Identification of pyroptosis related subtypes and tumor microenvironment infiltration characteristics in breast cancer.

Authors:  Guo Huang; Jun Zhou; Juan Chen; Guowen Liu
Journal:  Sci Rep       Date:  2022-06-23       Impact factor: 4.996

2.  STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer.

Authors:  Qiwei Wang; Johann S Bergholz; Liya Ding; Ziying Lin; Sheheryar K Kabraji; Melissa E Hughes; Xiadi He; Shaozhen Xie; Tao Jiang; Weihua Wang; Jason J Zoeller; Hye-Jung Kim; Thomas M Roberts; Panagiotis A Konstantinopoulos; Ursula A Matulonis; Deborah A Dillon; Eric P Winer; Nancy U Lin; Jean J Zhao
Journal:  Nat Commun       Date:  2022-05-31       Impact factor: 17.694

3.  Chitosan oligosaccharide decorated liposomes combined with TH302 for photodynamic therapy in triple negative breast cancer.

Authors:  Yinan Ding; Rui Yang; Weiping Yu; Chunmei Hu; Zhiyuan Zhang; Dongfang Liu; Yanli An; Xihui Wang; Chen He; Peidang Liu; Qiusha Tang; Daozhen Chen
Journal:  J Nanobiotechnology       Date:  2021-05-19       Impact factor: 10.435

4.  Tumor Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Human Breast Cancer Are Mediated by PD-L1-S283 and Chemokine Axes.

Authors:  Nofar Erlichman; Tamir Baram; Tsipi Meshel; Dina Morein; Benny Da'adoosh; Adit Ben-Baruch
Journal:  Cancers (Basel)       Date:  2022-02-18       Impact factor: 6.575

5.  Light-controllable charge-reversal nanoparticles with polyinosinic-polycytidylic acid for enhancing immunotherapy of triple negative breast cancer.

Authors:  Lei Fang; Zitong Zhao; Jue Wang; Ping Xiao; Xiangshi Sun; Yaping Ding; Pengcheng Zhang; Dangge Wang; Yaping Li
Journal:  Acta Pharm Sin B       Date:  2021-06-15       Impact factor: 11.413

6.  Chemotherapy-induced COX-2 upregulation by cancer cells defines their inflammatory properties and limits the efficacy of chemoimmunotherapy combinations.

Authors:  Victoria S Pelly; Agrin Moeini; Shih-Chieh Chiang; Charlotte R Bell; Eimear Flanagan; Christian P Bromley; Christopher Clark; Charles H Earnshaw; Maria A Koufaki; Eduardo Bonavita; Santiago Zelenay
Journal:  Nat Commun       Date:  2022-04-19       Impact factor: 17.694

7.  A risk model of 10 aging-related genes for predicting survival and immune response in triple-negative breast cancer.

Authors:  Xia Yang; Yanhua Sun; Xia Liu; Zhinong Jiang
Journal:  Cancer Med       Date:  2022-03-16       Impact factor: 4.711

8.  Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy.

Authors:  Zaofeng Yang; Jacquelyne Ka-Li Sun; Marianne M Lee; Michael K Chan
Journal:  J Immunother Cancer       Date:  2022-09       Impact factor: 12.469

Review 9.  Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer.

Authors:  Amy H Tang; Richard A Hoefer; Mary L Guye; Harry D Bear
Journal:  Cancer Drug Resist       Date:  2022-06-22
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.